BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 19834313)

  • 21. Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study.
    Trolle B; Lauszus FF; Frystyk J; Flyvbjerg A
    Fertil Steril; 2010 Nov; 94(6):2234-8. PubMed ID: 20189560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
    Ibáñez L; de Zegher F
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of drospirenone-ethinyl estradiol and drospirenone-ethinyl estradiol + metformin on ovarian ultrasonographic markers, body fat mass index, leptin, and ghrelin.
    Cakiroglu Y; Vural B; Isgoren S
    Arch Gynecol Obstet; 2013 Jul; 288(1):213-20. PubMed ID: 23377194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial.
    Soldat-Stanković V; Popović-Pejičić S; Stanković S; Prtina A; Malešević G; Bjekić-Macut J; Livadas S; Ognjanović S; Mastorakos G; Micić D; Macut D
    J Endocrinol Invest; 2022 Mar; 45(3):583-595. PubMed ID: 34665453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance.
    O'Connor A; Phelan N; Tun TK; Boran G; Gibney J; Roche HM
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1378-85. PubMed ID: 20080859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome.
    Kaya MG; Calapkorur B; Karaca Z; Yildirim S; Celik A; Akpek M; Unluhizarci K; Kelestimur F
    Clin Endocrinol (Oxf); 2012 Dec; 77(6):885-92. PubMed ID: 22563947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.
    Tfayli H; Ulnach JW; Lee S; Sutton-Tyrrell K; Arslanian S
    J Clin Endocrinol Metab; 2011 May; 96(5):1311-9. PubMed ID: 21325466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiandrogenic contraceptives increase serum adiponectin in obese polycystic ovary syndrome patients.
    Luque-Ramírez M; Alvarez-Blasco F; Escobar-Morreale HF
    Obesity (Silver Spring); 2009 Jan; 17(1):3-9. PubMed ID: 18997670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
    Esfahanian F; Zamani MM; Heshmat R; Moini nia F
    J Obstet Gynaecol Res; 2013 Apr; 39(4):806-13. PubMed ID: 23279603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-molecular-weight adiponectin is inversely associated with sympathetic activity in polycystic ovary syndrome.
    Shorakae S; Abell SK; Hiam DS; Lambert EA; Eikelis N; Jona E; Sari CI; Stepto NK; Lambert GW; de Courten B; Teede HJ
    Fertil Steril; 2018 Mar; 109(3):532-539. PubMed ID: 29428305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment.
    Zheng S; Liu E; Zhang Y; Long T; Liu X; Gong Y; Mai T; Shen H; Chen H; Lin R; Zheng Y; Xie Y; Wang F
    Endocr J; 2019 Jun; 66(6):555-562. PubMed ID: 30918134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
    Elkind-Hirsch K; Marrioneaux O; Bhushan M; Vernor D; Bhushan R
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2670-8. PubMed ID: 18460557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss.
    Spanos N; Tziomalos K; Macut D; Koiou E; Kandaraki EA; Delkos D; Tsourdi E; Panidis D
    Obes Facts; 2012; 5(4):495-504. PubMed ID: 22854419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metformin increases the novel adipokine cartonectin/CTRP3 in women with polycystic ovary syndrome.
    Tan BK; Chen J; Hu J; Amar O; Mattu HS; Adya R; Patel V; Ramanjaneya M; Lehnert H; Randeva HS
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1891-900. PubMed ID: 24152681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial.
    Sahu A; Tripathy P; Mohanty J; Nagy A
    J Gynecol Obstet Hum Reprod; 2019 May; 48(5):335-339. PubMed ID: 30316907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.
    Costello M; Shrestha B; Eden J; Sjoblom P; Johnson N
    Cochrane Database Syst Rev; 2007 Jan; (1):CD005552. PubMed ID: 17253562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adiponectin and leptin levels in normal weight women with polycystic ovary syndrome.
    Gözüküçük M; Yarcı Gürsoy A; Destegül E; Taşkın S; Şatıroğlu H
    Horm Mol Biol Clin Investig; 2020 May; 41(4):. PubMed ID: 32364518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Association between levels of serum leptin and insulin resistance in patients with polycystic ovary syndrome].
    Cheng X; Guo J; Xie J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Dec; 35(12):1389-91. PubMed ID: 25623461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
    Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR
    Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.